Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1796234 | 0.85 | PLA2G2A (0.50) | PLA2G2AMAPTRAB9AALPLPTGES | |
| SCHEMBL2771698 | 0.83 | MAPT (0.58) | PLA2G2AMAPTRAB9AESR1ALPL | |
| SCHEMBL10268140 | 0.82 | PLA2G2A (0.55) | PLA2G2AMAPTRAB9AALPLNPC1 | |
| SCHEMBL2666576 | 0.82 | PLA2G2A (0.47) | PLA2G2AMAPTRAB9AALPLPTGES | |
| SCHEMBL13461247 | 0.80 | PLA2G2A (0.54) | PLA2G2AMAPTRAB9AALPLNPC1 | |
| SCHEMBL2666575 | 0.80 | PLA2G2A (0.43) | PLA2G2AMAPTRAB9AALPLPTGES | |
| SCHEMBL25327393 | 0.80 | PLA2G2A (0.71) | PLA2G2AMAPTESR1SMPD1 | |
| SCHEMBL15731932 | 0.80 | PLA2G2A (0.71) | PLA2G2AMAPTESR1SMPD1 | |
| SCHEMBL1568668 | 0.80 | PLA2G2A (0.71) | PLA2G2AMAPTESR1SMPD1 | |
| SCHEMBL5086867 | 0.80 | PLA2G2A (0.71) | PLA2G2AMAPTESR1SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977328-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-07-12 | — | — | US | disclosed |
| US-7943607-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| EP-2305674-A1 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| EP-2301929-A1 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | AstraZeneca AB (Publ) (SE) | 2011-03-30 | — | — | EP | disclosed |
| EP-2301935-A1 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | AstraZeneca AB (Publ) (SE) | 2011-03-30 | — | — | EP | disclosed |
| US-20110053910-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | ASTRAZENECA AB (SE) | 2011-03-03 | — | — | US | disclosed |
| US-7842694-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2010-11-30 | — | — | US | disclosed |
| US-20100160286-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | ASTRAZENECA UK LIMITED AB (SE) | 2010-06-24 | — | — | US | disclosed |
| US-7642259-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2010-01-05 | — | — | US | disclosed |
| US-7642263-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2010-01-05 | — | — | US | disclosed |
| US-20090264336-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-20090118159-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20090111790-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090105214-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| WO-2007017649-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007007041-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007007040-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006125972-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105214-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | GCK, GCKR, GK | PLA2G2A 521/4885MAPT 4875/4885RAB9A 3044/4885 |
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | PLA2G2A 475/4885MAPT 4881/4885RAB9A 3143/4885 |
| US-20090111790-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | PLA2G2A 555/4885MAPT 4877/4885RAB9A 2935/4885 |
| US-20100160286-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | GCK, GCKR, HK1 | PLA2G2A 1516/4885MAPT 4880/4885RAB9A 3433/4885 |
| US-20090118159-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | PLA2G2A 555/4885MAPT 4877/4885RAB9A 2935/4885 |
| US-20110053910-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | GCK, GCKR, HK1 | PLA2G2A 658/4885MAPT 4878/4885RAB9A 3060/4885 |
| US-20090264336-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | PLA2G2A 555/4885MAPT 4877/4885RAB9A 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.